FreeStyle Libre Glucose Monitoring System in Pediatric Populations

NCT03502174 | Completed FDA Device

• 1 other identifier: ADC-US-VAL-18172
• Study Type: observational
• Target: 63
• Locations: 1 country
• Sites: 3

Brief Summary

This study is a non-randomized, single-arm, multi-center study that is designed to evaluate the safety and effectiveness of the FreeStyle Libre Flash Glucose Monitoring Systems in pediatric populations.

Conditions

Diabetes Mellitus

Outcome Measures

Primary Outcomes (2)

• FreeStyle Libre Flash Glucose Monitoring System Performance

  System performance will be characterized with respect to YSI reference venous plasma sample measurements. Point accuracy of the system will be evaluated as the proportion of System readings that are within ±20% of the YSI reference value for YSI glucose levels ≥ 80 mg/dl and within ±20 mg/dl for YSI glucose levels \<80 mg/dl.

  up to 14 days

• FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects

  System will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.

  up to 45 days

Interventions

FreeStyle Libre Flash Glucose Monitoring System DEVICE

Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.

Eligibility Criteria

• Age: 6 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Subjects aged 6-17 years, with type 1 or type 2 diabetes who currently perform capillary blood glucose (BG) testing at least four (4) times a day.

You may qualify if:

• Subject must be at least 6 years of age.
• Subject must weigh at least 26 kg (57.2 lbs.).
• Subject must have a diagnosis of type 1 or type 2 diabetes mellitus
• Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
• Subject must be currently performing at least four (4) capillary blood glucose tests per day.
• Subject is willing to perform a minimum of 4 finger sticks per day during the study.
• Subject is willing to allow medical personnel to insert at IV catheter in the arm to allow for venous blood samples to be obtained per the study protocol.
• Subject and/or guardian must be able to read and understand English.
• In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
• Subject must be available to participate in all study visits.
• Subject must be willing and able to provide written signed and dated informed assent when appropriate.
• Subject's parent, guardian or legally authorized representative must be willing and able to provide written informed consent.

You may not qualify if:

• Subject is 18 years of age or older.
• Subject weighs less than 26 kg (57.2 lbs.).
• Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
• Subject is known to be pregnant or becomes pregnant during the study (applicable to female subjects only).
• Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
• Subject is currently participating in another clinical trial.
• Subject has had significant blood loss within 112 days (3.7 months) prior to the beginning of the study activities subjects.
• Subject is anemic, defined as having hemoglobin levels below 11.5 g/dL for subjects aged 6-11 years old, less than 12.0 g/dL for subjects aged 12-15 years old, less than 12.0 g/dL for females aged 15-17 and less than 13.0 g/dL for males aged 15-171, or as determined by investigator.
• Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
• Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Sponsors & Collaborators

• Abbott Diabetes Care: lead

Study Sites (3)

Sansum Diabetes Research Institute

Santa Barbara, California, 93105, United States

Location

Diablo Clinical Research

Walnut Creek, California, 94598, United States

Location

Rocky Mountain Diabetes & Osteoporosis Center

Idaho Falls, Idaho, 83404, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Shridhara Alva, PhD

  Abbot Diabetes care inc.

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 4, 2018
• First Posted: April 18, 2018
• Study Start: April 5, 2018
• Primary Completion: July 3, 2018
• Study Completion: July 3, 2018
• Last Updated: January 28, 2019

Record last verified: 2018-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)